Literature DB >> 6279691

Improved immunofluorescence antigens for detection of immunoglobulin M antibodies to Epstein-Barr viral capsid antigen and antibodies to Epstein-Barr virus nuclear antigen.

D Gallo, K H Walen, J L Riggs.   

Abstract

Epstein-Barr viral capsid antigen and nuclear antigen produced by modified procedures were evaluated for use in measuring viral capsid antigen immunoglobulin M and Epstein-Barr virus nuclear antigen antibody responses in sera from patients with suspected Epstein-Barr virus infections. Viral capsid antigen production was stimulated with a phorbol ester, and the Epstein-Barr virus nuclear antigen cells were fixed in suspension to eliminate loss of antigen during the drying process. Both preparations proved to be sensitive and reliable.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6279691      PMCID： PMC272069          DOI： 10.1128/jcm.15.2.243-248.1982

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  12 in total

1.  A prospective evaluation of heterophile and Epstein-Barr virus-specific IgM antibody tests in clinical and subclinical infectious mononucleosis: Specificity and sensitivity of the tests and persistence of antibody.

Authors:  A S Evans; J C Niederman; L C Cenabre; B West; V A Richards
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

Review 2.  The immunological approach to study of possibly virus-induced human malignancies using the Epstein-Barr virus as example.

Authors:  W Henle; G Henle
Journal:  Prog Exp Tumor Res       Date:  1978

3.  Persisting oncogenic herpesvirus induced by the tumour promotor TPA.

Authors:  H zur Hausen; F J O'Neill; U K Freese; E Hecker
Journal:  Nature       Date:  1978-03-23       Impact factor: 49.962

4.  Anti-complement immunofluorescence test for antibodies to human cytomegalovirus.

Authors:  J D Kettering; N J Schmidt; D Gallo; E H Lennette
Journal:  J Clin Microbiol       Date:  1977-12       Impact factor: 5.948

5.  Antibodies to Epstein-Barr virus-associated nuclear antigen in infectious mononucleosis.

Authors:  G Henie; W Henle; C A Horwitz
Journal:  J Infect Dis       Date:  1974-09       Impact factor: 5.226

Review 6.  Epstein-Barr virus specific diagnostic tests in infectious mononucleosis.

Authors:  W Henle; G E Henle; C A Horwitz
Journal:  Hum Pathol       Date:  1974-09       Impact factor: 3.466

7.  Evaluation of Epstein-Barr virus-associated nuclear antigen with various human cell lines.

Authors:  M Suzuki; Y Hinuma
Journal:  Int J Cancer       Date:  1974-12-15       Impact factor: 7.396

8.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

9.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

10.  Endogenous reactivation of Epstein-Barr virus infections.

Authors:  C V Sumaya
Journal:  J Infect Dis       Date:  1977-03       Impact factor: 5.226
View more
  4 in total

1.  Indirect alkaline phosphatase immunoenzymatic staining for the detection of antibodies to Epstein-Barr virus-induced virus capsid antigens and early antigens.

Authors:  M Musiani; M Zerbini; G Gentilomi; M La Placa
Journal:  J Clin Microbiol       Date:  1986-02       Impact factor: 5.948

2.  Immunocytochemical detection of antibodies to Epstein-Barr virus nuclear antigen by a streptavidin-biotin-complex assay.

Authors:  M Musiani; M Zerbini; M Plazzi; G Gentilomi; M La Placa
Journal:  J Clin Microbiol       Date:  1988-05       Impact factor: 5.948

3.  Use of a simple separation column in detection of immunoglobulin M antibody to Epstein-Barr virus.

Authors:  C V Sumaya; Y Ench; M A Carrillo; R M Pope
Journal:  J Clin Microbiol       Date:  1984-08       Impact factor: 5.948

4.  Viral and toxoplasma gondii infections in children after liver transplantation.

Authors:  A Salt; G Sutehall; M Sargaison; C Woodward; N D Barnes; R Y Calne; T G Wreghitt
Journal:  J Clin Pathol       Date:  1990-01       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.